The subsequent chapters of this book are pitched explicitly to pharmacists and doctors and deal in greater detail with the various scientific, clinical, economic, QUM, and pharmacovigilance aspects of innovator biologics, biosimilars, and biobetters. The material provided in this and subsequent chapters should facilitate discussions by pharmacists with doctors and patients on these expensive and highly effective medicines so that the full therapeutic potential of all biologic medicines is realized in a timely manner.
Acknowledgement
The author thanks Dr Reza Kahlaee for expert assistance with collation of the cited references.
References
1 1 Davies, N. (2018). The future of biologics. Pharm Lett www.thepharmaletter.com/article/the‐future‐of‐biologics (accessed 20 June 2020).
2 2 Sarpatwari, A., Barenie, R., Curfman, G. et al. (2019). The US biosimilar market: stunted growth and possible reforms. Clin Pharmacol Ther 105 (1): 92–100.
3 3 Dutta, B., Huys, I., Vulto, A.G., and Simoens, S. (2019). Identifying key benefits in European off‐patent biologics and biosimilar markets: it is not only about price! BioDrugs 34 (Suppl. 3): 159–170. https://doi.org/10.1007/s40259‐019‐00395‐w.
4 4 Johnson, I. (1983). Human insulin from recombinant DNA technology. Science 219 (4585): 632–637.
5 5 WHO (2009). Health Organization expert committee on biological standardization. Guidelines on evaluation of similar biotherapeutic products (SBPs). https://www.who.int/biologicals/publications/trs/areas/biological_therapeutics/TRS_977_Annex_2.pdf?ua=1 (accessed 17 February 2020).
6 6 Declerck, P. and Farouk, R.M. (2017). The road from development to approval: evaluating the body of evidence to confirm biosimilarity. Rheumatology (Oxford) 56 (suppl 4): iv4–iv13.
7 7 Beyer, B., Walch, N., Jungbauer, A., and Lingg, N. (2019). How similar is biosimilar? A comparison of infliximab therapeutics in regard to charge variant profile and antigen binding affinity. Biotechnol J 14 (4): e1800340.
8 8 Nick, C. (2015). Quality attributes in the making and breaking of biosimilarity. Regul Rapporteur 12 (9): 10–13.
9 9 Dahodwala, H. and Sharfstein, S.T. (2017). Biosimilars: imitation games. ACS Med Chem Lett 8 (7): 690–693.
10 10 Zhang, A., Tzeng, J.‐Y., and Chow, S.‐C. (2013). Statistical considerations in biosimilar assessment using biosimilarity index. J Bioequivalence Bioavailab 5 (5): 209–214.
11 11 Beck, A. and Reichert, J.M. (2013). Approval of the first biosimilar antibodies in Europe: a major landmark for the biopharmaceutical industry. MAbs 5 (5): 621–623.
12 12 Mehr, S.R. and Zimmerman, M.P. (2016). Is a biologic produced 15 years ago a biosimilar of itself today? Am Health Drug Benefits 9 (9): 515–518.
13 13 Webster, C.J. and Woollett, G.R. (2017). A ‘global reference' comparator for biosimilar development. BioDrugs 31 (4): 279–286.
14 14 Diependaele, L., Cockbain, J., and Sterckx, S. (2018). Similar or the same? Why biosimilars are not the solution. J Law Med Ethics 46 (3): 776–790.
15 15 Pani, L., Montilla, S., Pimpinella, G., and Bertini, M.R. (2013). Biosimilars: the paradox of sharing the same pharmacological action without full chemical identity. Expert Opin Biol Ther 13 (10): 1343–1346.
16 16 Blanchard, A., D'Iorio, H., and Ford, R. (2010). What you need to know to succeed: key trends in Canada’s biotech industry. Insight 1 (Spring).
17 17 Mechcatie, E. (2010). FDA asks: when are biosimilars similar enough? Commun Oncol 8 (10): 479–480.
18 18 Murphy, C., Sugrue, K., Mohamad, G. et al. (2015). P505: biosimilar but not the same. Paper presented at 10th Congress of ECCO2015, Barcelona, Spain (January 2015).
19 19 Vijayalakshmi, R., Sabitha, K., and Arvind, K. (2012). How dissimilarly similar are biosimilars? Int Res J Pharm 3 (5): 12–16.
20 20 Ronco, C. (2005). Biosimilars: how similar are they? Int J Artif Organs 28 (6): 552–553.
21 21 Jeffrey, K. and Ferner, R. (2016). How similar are biosimilars? BMJ Online 353: i2721.
22 22 Gupta, P. (2017). Biosimilars: similar but not the same. JK Sci 19 (2): 67–69.
23 23 Dingermann, T. and Zündorf, I. (2007). Biosimilars: similar, but not the same. Dtsch Apoth Ztg 147 (38): 68–74.
24 24 Dingermann, T. and Zündorf, I. (2015). Same, similar or different? How biosimilars can differ from originals. Dtsch Apoth Ztg 155 (7).
25 25 Schellekens, H. (2004). How similar do ‘biosimilars' need to be? Nat Biotechnol 22 (11): 1357–1359.
26 26 Schellekens, H. and Moors, E. (2015). Biosimilars or semi‐similars? Nat Biotechnol 33 (1): 19–20.
27 27 Rudolf, T., Brinkmann, C., and Bleiziffer, A. (2015). Biosimilars‐necessary alternative or overpriced me‐toos? Pharm Ind 77 (2): 160–165.
28 28 Rolf, D., Parker, J., and Morgan, M. (2016). Are biosimilars patentable? Expert Opin Ther Pat 26 (8): 871–875.
29 29 Guillon‐Munos, A., Daguet, A., and Watier, H. (2014). Antibody biosimilars: fears or opportunities? First LabEx MabImprove Workshop. MAbs 6 (4): 805–809.
30 30 Declerck, P., Danesi, R., Petersel, D., and Jacobs, I. (2017). The language of biosimilars: clarification, definitions, and